Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus TRIPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus TRIPHED.
SEMPREX-D vs TRIPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating symptoms of allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing edema.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
Adults: Triprolidine 2.5 mg / pseudoephedrine 60 mg orally every 4-6 hours, not to exceed 4 doses in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Terminal elimination half-life is 6-8 hours in adults with normal renal function; clinically, dosing interval adjustments are recommended in renal impairment.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Renal excretion of unchanged drug and metabolites accounting for approximately 60-70% of elimination; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination